Combination therapy for the treatment of cancer

A method of treating cancer, comprising administering to a subject in need thereof:

• (A) a Variant Chimeric 4D5 Antibody comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:4, and a heavy chain that comprises a variant Fc Region that exhibits enhanced ADCC activity relative to a comparable antibody that comprises a wild-type IgG1 Fc Region, wherein said heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13, and
• (B) an anti-PD-1 antibody or a molecule that specifically binds PD-1 that comprises an antigen-binding fragment of said anti-PD-1 antibody, wherein said anti-PD-1 antibody and said antigen-binding fragment comprise:
• (a) a variant Fc Region that comprises at least one modification relative to a wild-type IgG1 Fc Region or an IgG4 Fc Region, wherein said variant Fc Region of said molecule exhibits reduced ADCC activity relative to a comparable molecule that comprises said wild-type IgG1 Fc Region;
• and
• (b)
• (1) the three heavy chain CDRs and the three light chain CDRs of antibody hPD-1 mAb 2;
• (2) the three heavy chain CDRs and the three light chain CDRs of antibody PD-1 mAb 6-ISQ;
• (3) the three heavy chain CDRs and the three light chain CDRs of antibody hPD-1 mAb 7;
• (4) the three heavy chain CDRs and the three light chain CDRs of antibody hPD-1 mAb 9;
• or
• (5) the three heavy chain CDRs and the three light chain CDRs of antibody hPD-1 mAb 15.